ArticleAsian Pacific journal of cancer prevention : APJCP2025
In Vitro Anticancer Activities of Senna singueana Leaf Extracts against HeLa Cell Lines.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe present demonstrated that SSL-CH extract selectively inhibits the growth of HeLa cell lines though activation of p53 and Bax genes medaied proapoptotic pathway signifying it is a potential alternative anticancer agent for cervical cancer. MATERIALS AND
methodsThe selective cytotoxicity of diethyl ether, chloroform, ethyl acetate, and ethanolic leaf extracts of S. singueana were evaluated against cervical HeLa and normal mouse fibroblast L929 cell lines using MTT assay. At (IC50) concentration 20 µg/ml) of effective chloroform leaf extract of S. singueana (SSL-CH) was chosen to evaluate its nuclear apoptotic changes by using Acridine Orange/Etidium Bromide dual staining. Subsequently, apoptotic induction potential of SSL-CH extract was assessed by RT-qPCR analysis of apoptotic genes p53 and Bax.
resultsTreatment SSL-CH extract selectively inhibited the dose depended proflretion of HeLa cell lines with IC50 of 20 µg/ml. AO/EB dual staining showed SSL-CH extract induced late apoptosis of 49.42% in compared to the control. RT-PCR analyses demonstrated that SSL-CH extract profoundly upregulated the proapoptotic genes p53 to12.85 (***p≤0.01), Bax to 11.61 (**p≤0.01), caspase-9 to 40.62 (***p≤0.01), and caspase-3 to 11.61 folds (**p≤0.01) respectively and down regulated antiapoptotic genes Bcl-2 to 0.9 (**p≤0.001) and survivin gene to 1 (***p≤0.001) at 2×IC50 (40 µg/mL) in comparison to control, confirming activation of the intrinsic apoptotic pathway.
conclusionThese findings demonstrated that SSL-CH extract could serve as a potential alternative therapeutic agent for cervical cancer treatment with affordable and fewer side effects comparison with cisplatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.